Technical Analysis for AXSM - Axsome Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| 20 DMA Support | Bullish | -0.90% | |
| 180 Bullish Setup | Bullish Swing Setup | -0.90% | |
| Outside Day | Range Expansion | -0.90% | |
| Calm After Storm | Range Contraction | 2.33% | |
| Down 3 Days in a Row | Weakness | 2.33% | |
| Down 4 Days in a Row | Weakness | 2.33% | |
| Upper Bollinger Band Touch | Strength | 1.53% | |
| Down 3 Days in a Row | Weakness | 1.53% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Up 1% | about 21 hours ago |
| 10 DMA Support | about 22 hours ago |
| Bullish 180 Entry | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of pain and other central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of pain in patients with complex regional pain syndrome; and AXS-05 for the treatment of agitation in patients with Alzheimer's disease and treatment resistant depression. The company is also developing AXS-02 for the treatment of knee osteoarthritis and chronic low back pain, as well as a preclinical development program AXS-06 for the treatment of chronic pain disorders. Axsome Therapeutics, Inc. was founded in 2012 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pain Organ Systems Clinical Development Alzheimer's Disease Chronic Pain Pain Management Depression Central Nervous System Disorders Nervous System Disorders Osteoarthritis Knee Chronic Condition Antidepressants Treatment Of Chronic Pain Back Pain Treatment Resistant Depression
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pain Organ Systems Clinical Development Alzheimer's Disease Chronic Pain Pain Management Depression Central Nervous System Disorders Nervous System Disorders Osteoarthritis Knee Chronic Condition Antidepressants Treatment Of Chronic Pain Back Pain Treatment Resistant Depression
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 105.0 |
| 52 Week Low | 60.28 |
| Average Volume | 462,443 |
| 200-Day Moving Average | 82.59 |
| 50-Day Moving Average | 90.76 |
| 20-Day Moving Average | 91.80 |
| 10-Day Moving Average | 94.21 |
| Average True Range | 3.73 |
| RSI (14) | 55.36 |
| ADX | 16.55 |
| +DI | 29.80 |
| -DI | 20.58 |
| Chandelier Exit (Long, 3 ATRs) | 93.80 |
| Chandelier Exit (Short, 3 ATRs) | 97.26 |
| Upper Bollinger Bands | 98.47 |
| Lower Bollinger Band | 85.14 |
| Percent B (%b) | 0.71 |
| BandWidth | 14.53 |
| MACD Line | 1.46 |
| MACD Signal Line | 1.17 |
| MACD Histogram | 0.2914 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 98.62 | ||||
| Resistance 3 (R3) | 98.95 | 97.93 | 97.95 | ||
| Resistance 2 (R2) | 97.93 | 96.91 | 97.77 | 97.73 | |
| Resistance 1 (R1) | 96.27 | 96.28 | 95.76 | 95.94 | 97.50 |
| Pivot Point | 95.25 | 95.25 | 95.00 | 95.09 | 95.25 |
| Support 1 (S1) | 93.59 | 94.23 | 93.08 | 93.26 | 91.70 |
| Support 2 (S2) | 92.57 | 93.60 | 92.41 | 91.47 | |
| Support 3 (S3) | 90.91 | 92.57 | 91.25 | ||
| Support 4 (S4) | 90.58 |
